Pegozafermin associated with improved outcomes in nonalcoholic steatohepatitis

1. In this randomized controlled trial, treatment with pegozafermin improved fibrosis in patients with nonalcoholic steatohepatitis (NASH). 2. Treatment with pegozafermin led to increased rates of NASH resolution. Evidence Rating Level: 1 (Excellent) Study Rundown: NASH is a disease characterized by hepatic inflammation and excess fat accumulation with or without fibrosis of the liver. Pegozafermin

Related Keywords

,Minute Medicine Inc ,Rating Level ,Controlled Trial ,Confidence Interval ,Chronic Disease ,Fibrosis ,Gastroenterology ,Hepatology ,Hypertriglyceridemia ,Nash ,Nonalcoholic Steatohepatitis Outcomes ,Pegozafermin ,Recombinant Fibroblast Growth Factor 21 Analog ,